Affordable Access

The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial.

Authors
Type
Published Article
Journal
The Journal of clinical endocrinology and metabolism
Publication Date
Volume
92
Issue
4
Pages
1305–1310
Identifiers
PMID: 17264176
Source
Medline

Abstract

Statistics

Seen <100 times